Articles from Transcripta Bio

Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular diseases, today announced it has raised $24 million since its Series A to advance IND-enabling studies across its portfolio and support clinical preparation in its Autism Spectrum Disorder (ASD) and Facioscapulohumeral Muscular Dystrophy (FSHD) programs. Mayo Clinic and Omnimed join existing investors JAZZ Venture Partners, BlueYard Capital, and a group of life sciences family offices as the company advances its pipeline toward human clinical trials. The company's pipeline spans four programs across Myotonic Dystrophy, FSHD, ASD, and Huntington's Disease (HD).

Transcripta Bio, a platform drug development biotechnology company that is revolutionizing discovering and developing medicines at unprecedented speed, scale, and capital efficiency, has been included in the fourth-annual TIME100 Most Influential Companies list. The prestigious list spotlights companies around the world that are making an extraordinary impact and recognizes Transcripta Bio’s significant achievements in speeding drug discovery.